Forbion reports 7.1% stake in MapLight
Forbion Growth Opportunities Fund III Cooperatief U.A. and Forbion Growth III Management B.V. report a 7.1% beneficial ownership stake in MapLight Therapeutics, Inc. voting common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Forbion Growth Opportunities Fund III Cooperatief U.A. and Forbion Growth III Management B.V. report a 7.1% beneficial ownership stake in MapLight Therapeutics, Inc. voting common stock. They beneficially own 3,226,400 shares with shared voting and dispositive power and no sole power over any shares. This percentage is based on 45,373,033 MapLight common shares outstanding as of November 24, 2025, as cited from the company’s Form 10-Q. Both reporting entities are organized in the Netherlands and file jointly on this Schedule 13G.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of MapLight Therapeutics (MPLT) does Forbion’s stake represent?
Which entities are the reporting persons in the MapLight (MPLT) Schedule 13G?
Where are the Forbion reporting entities in the MapLight (MPLT) filing organized and located?
AI-generated analysis. How Rhea-AI works. Not financial advice.